Kishi Taro, Iwata Nakao
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Int J Neuropsychopharmacol. 2014 Feb;17(2):343-54. doi: 10.1017/S1461145713000667. Epub 2013 Jul 3.
We examined whether noradrenergic and specific serotonergic antidepressants (NaSSAs: mirtazapine and mianserin), as augmentation therapy, have therapeutic potential for schizophrenia treatment. A systematic review was conducted of PubMed, Cochrane Library and PsycINFO in December 2012 and meta-analyses of double-blind, randomized placebo-controlled trials were performed. Standardized mean difference (SMD), risk ratio (RR), number-needed-to-treat (NNT), number-needed-to-harm (NNH) and 95% confidence intervals (CI) were calculated. Results were across 12 studies and 362 patients were included (mirtazapine: seven trials and 221 patients; mianserin: five trials and 141 patients). NaSSA augmentation therapy was superior to placebo in overall symptoms (S.M.D. = -0.75, CI -1.24 to -0.26, p = 0.003, N = 11, n = 301), negative symptoms (S.M.D. = -0.88, CI -1.41 to -0.34, p = 0.001, N = 9, n = 240) and response rate (RR = 0.71, CI 0.57-0.88, p = 0.002, NNT = 4, p<0.00001, N = 6, n = 163). There was no significant difference in positive symptoms, depressive symptoms or discontinuation rate between NaSSAs and placebo treatments. In addition, no patients who received NaSSAs developed worsening psychosis during the study. For individual NaSSAs, mirtazapine was superior to placebo in overall symptoms (S.M.D. = 0.98, CI = -1.74 to -0.22, p = 0.01, N = 7, n = 194), negative symptoms (S.M.D. = -1.25, CI -1.88 to -0.62, p = 0.0001, N = 6, n = 172) and response rate (RR = 0.70, p = 0.04, NNT = 4, p = 0.0004, N = 4, n = 119). Moreover, NaSSAs were associated with reduced akathisia score (p < 0.00001) and extrapyramidal symptom scales (p = 0.01). However, NaSSAs caused drowsiness/sedation/somnolence compared with placebo (RR = 3.52, p = 0.002, NNT = 6, p = 0.01, N = 8, n = 209). Our results indicate that NaSSA (especially mirtazapine) augmentation therapy improved overall and negative symptoms in patients with schizophrenia. Because the included studies were small, the results should be treated with caution.
我们研究了去甲肾上腺素能和特异性5-羟色胺能抗抑郁药(NaSSAs:米氮平和米安色林)作为增效疗法,对精神分裂症治疗是否具有治疗潜力。2012年12月对PubMed、Cochrane图书馆和PsycINFO进行了系统评价,并对双盲、随机、安慰剂对照试验进行了荟萃分析。计算了标准化均数差(SMD)、风险比(RR)、治疗所需人数(NNT)、伤害所需人数(NNH)和95%置信区间(CI)。结果来自12项研究,纳入362例患者(米氮平:7项试验,221例患者;米安色林:5项试验,141例患者)。NaSSAs增效疗法在总体症状(SMD=-0.75,CI -1.24至-0.26,p=0.003,N=11,n=301)、阴性症状(SMD=-0.88,CI -1.41至-0.34,p=0.001,N=9,n=240)和缓解率(RR=0.71,CI 0.57 - 0.88,p=0.002,NNT=4,p<;0.00001,N=6,n=163)方面优于安慰剂。在阳性症状、抑郁症状或停药率方面,NaSSAs与安慰剂治疗之间无显著差异。此外,接受NaSSAs治疗的患者在研究期间均未出现精神病症状恶化。对于单个NaSSAs,米氮平在总体症状(SMD=-0.98,CI=-1.74至-0.22,p=0.01,N=7,n=194)、阴性症状(SMD=-1.25,CI -1.88至-0.62,p=0.0001,N=6,n=172)和缓解率(RR=0.70,p=0.04,NNT=4,p=0.0004,N=4,n=119)方面优于安慰剂。此外,NaSSAs与静坐不能评分降低(p<;0.00001)和锥体外系症状量表评分降低(p=0.01)相关。然而,与安慰剂相比,NaSSAs导致嗜睡/镇静/困倦(RR=3.52,p=0.002,NNT=6,p=0.01,N=8,n=209)。我们的结果表明,NaSSA(尤其是米氮平)增效疗法改善了精神分裂症患者的总体症状和阴性症状。由于纳入的研究规模较小,结果应谨慎对待。